Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer.

Genes, chromosomes & cancer - 1 Jul 2008

Zito Christina I, Riches David, Kolmakova Julia, Simons Jan, Egholm Michael, Stern David F

Abstract excerpt

Gene amplification is among the most common genetic abnormalities that cause cancer. One of the most clinically important gene amplifications in human cancer causes extensive reduplication of ERBB2. A variety of cancers also occasionally harbor somatic mutations in ERBB2. Gene amplification and activating mutations both have predictive value for clinical response to targeted inhibitors. Since the number of gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Neoplasm
Share to Gene Amplification

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Immunoprecipitation

Share to Mutagenesis, Site-Directed

Share to Open Reading Frames

Share to Receptor, ErbB-2

Share to Tumor Cells, Cultured

Source

Open in PubMed Open full text

Identifiers

PMID: 18418848
DOI: 10.1002/gcc.20566
PMCID: PMC6668724

Genes

ERBB2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer.PMID 18418848Read ↗

Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.Semantic proximity Read ↗

Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.Semantic proximity Read ↗

Targeted transcript quantification in single disseminated cancer cells after whole transcriptome amplificationSemantic proximity Read ↗

Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinomaSemantic proximity Read ↗

Real-Time Reverse Transcription-PCR Assay for Future Management of ERBB2-based Clinical ApplicationsSemantic proximity Read ↗

Activating HER2 mutations in HER2 gene amplification negative breast cancer.Semantic proximity Read ↗

Activation of multiple cancer-associated genes at the <i>ERBB2</i> amplicon in breast cancerSemantic proximity Read ↗

Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers.Semantic proximity Read ↗

Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCRSemantic proximity Read ↗

ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and PredictionSemantic proximity Read ↗

Alternative splicing enriched cDNA libraries identify breast cancer-associated transcripts.Semantic proximity Read ↗

Estimating copy number using next-generation sequencing to determine ERBB2 amplification statusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.